Quadruple Therapy Offers High SVR Rates in Patients with HCV Genotype 4 with Previous Treatment Failure
Background and Aims. Direct-acting antivirals (DAAs) have made a revolution in hepatitis C virus (HCV) treatment with promising reduction of HCV infection and disease morbidities. However, unfortunately, treatment failure still occurs in about 5–15% of patients treated with DAA‐based combination reg...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , |
|---|---|
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
Wiley
2020-01-01
|
| Schriftenreihe: | Advances in Virology |
| Online-Zugang: | http://dx.doi.org/10.1155/2020/9075905 |
| Tags: |
Keine Tags, Fügen Sie das erste Tag hinzu!
|